Clinical Trials Browser

Phase 1/2 × Biliary Tract Neoplasms × pembrolizumab × Clear all

NCT05849480 2026-02-05

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Phase 1/2 Recruiting

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms

NCT06428409 2026-01-22

MK-9999-02A

Phase 1/2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Colorectal Neoplasms

NCT07269158 2025-12-08

A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Phase 1/2 Not yet recruiting

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04956640 2025-09-25

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Phase 1/2 Recruiting

GastrointestinalGynecologicThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05784688 2025-03-30

Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Colorectal Neoplasms

NCT03937895 2022-03-29

Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer

Phase 1/2 Completed

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma